Efferon Unveils New Blood‑Purification System Aimed at Treating Pediatric Sepsis

The San Francisco‑based company Efferon has introduced a blood‑purification platform intended to tackle the high death rate of pediatric sepsis, presenting the device as a possible lifesaver for children in intensive care.

Pediatric sepsis continues to rank among the top causes of child mortality worldwide, responsible for hundreds of thousands of deaths each year despite progress in antibiotics and intensive‑care practices. The disorder occurs when the body’s reaction to infection escalates into a harmful inflammatory cascade, resulting in organ failure and often death.

Efferon’s approach relies on a small extracorporeal unit that filters the patient’s blood to extract surplus inflammatory mediators while leaving vital immune components intact. In contrast to conventional dialysis, the apparatus employs a proprietary sorbent designed to capture the cytokines most implicated in sepsis, enabling clinicians to act earlier in the disease progression.

The device originated in the Battlefield 200 accelerator, a program that backs early‑stage medical innovators. After completing pre‑clinical studies, Efferon is moving into a first‑in‑human feasibility trial across several pediatric intensive‑care units. The firm says the system satisfies key safety criteria and can be incorporated into existing hospital circuits without the need for extensive staff retraining.

Should trial results demonstrate effectiveness, the platform could address a longstanding void in sepsis therapy by offering a swift, mechanical way to blunt the damaging immune response. Health‑economics experts point out that curbing sepsis‑related complications may also reduce the hefty expenses tied to prolonged intensive‑care stays.

Obtaining regulatory approval will be the next major obstacle. Efferon intends to file a de novo request with the U.S. Food and Drug Administration later this year, while also pursuing collaborations with larger medical‑device manufacturers to scale production. Company leaders stress that the ultimate aim is to make the technology available in both well‑resourced hospitals and lower‑income environments where sepsis outcomes are typically poorer.